Background and objective: Surgical resection is the preferred treatment in selected patients with pulmonary neoplasms. In older than 70 years or have compromised cardiopulmonary status or coexistent medical problems patients, radiofrequency ablation (RFA) may offer an alternative option. The aim of this study is to evaluate the therapeutic effects after RFA in 100 patients with pulmonary neoplasms.
Methods: One hundred cases of unresectable lung tumors with 106 lesions were underwent RFA therapy. To evaluate the therapeutic effect and complications of lung tumors using spiral CT scanning and SPECT in 1-3 months after RFA.
Results: One hundred patients underwent RFA for lung neoplasms (62 men, 38 women; median age, 66.6 years; range, 36 to 91 years). Eighty-six patients with primary lung neoplasms and 14 patients with pulmonary metastases underwent RFA. Treatment was complete in all cases, no treatment-related deaths occurred in all of the 100 patients and serious morbidity associated with the procedures. The median overall survival for the entire group of patients was 13.0 months, the one and two years overall survival for total of were 51% and 32.5% respectively. No differences in overall survival noted between patients with primary and metastases lung neoplasms (P=0.922). The median overall survival for the early stage of patients was 28.0 months, 2-year overall survival for early stage primary lung cancer patients were 57.7%.
Conclusions: RFA is a safe and effective procedure in selective lung tumors. CT-guided radiofrequency ablation is a minimally invasive treatment option. RFA could act as an alternative treatment to inoperable lung cancer.
背景与目的: 手术切除是治疗肺部肿瘤的首选治疗手段，而对高龄、肺功能差的患者，射频消融治疗是一个很好的选择。本文总结了射频消融治疗100例肺部肿瘤的远期疗效和并发症。
方法: 对不能手术的100例肺部肿瘤患者行射频消融治疗，定期复查胸部增强CT扫描、肿瘤SPECT或PET显像并随访，观察远期疗效及并发症。
结果: 100例肺部肿瘤病例的106个病灶接受了射频消融治疗。其中男性62例，女性38例，年龄36岁-91岁，平均66.6岁。原发性肺癌86例，肺转移瘤14例。所有病例完成射频消融治疗，无严重并发症和围手术期死亡。全组总生存时间为13.0个月，1年生存率51.0%，2年生存率32.5%，原发性肺癌与肺转移瘤相比无统计学差异（P=0.922）。早期肺癌的中位生存时间为28个月，2年总生存率为57.7%。
结论: CT引导下射频消融治疗肺癌具有安全、有效、定位准确和微创的优点，是不能耐受手术的早期肺癌患者的选择之一，对中晚期肺癌是一种局部减瘤手段。